Target
RAF proto-oncogene serine/threonine-protein kinase
Ligand
BDBM50237711
Substrate
n/a
Meas. Tech.
ChEMBL_163344 (CHEMBL765226)
IC50
610±n/a nM
Citation
 Liverton, NJButcher, JWClaiborne, CFClaremon, DALibby, BENguyen, KTPitzenberger, SMSelnick, HGSmith, GRTebben, AVacca, JPVarga, SLAgarwal, LDancheck, KForsyth, AJFletcher, DSFrantz, BHanlon, WAHarper, CFHofsess, SJKostura, MLin, JLuell, SO'Neill, EAO'Keefe, SJ Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase. J Med Chem 42:2180-90 (1999) [PubMed]  Article 
Target
Name:
RAF proto-oncogene serine/threonine-protein kinase
Synonyms:
C-Raf Protein Kinase | Proto-oncogene c-RAF (RAF1) | RAF | RAF proto-oncogene serine/threonine-protein kinase (C-Raf) | RAF1 | RAF1_HUMAN | Raf-1 | Serine/threonine-protein kinase RAF | Serine/threonine-protein kinase C-Raf | cRaf
Type:
Serine/threonine-protein kinase
Mol. Mass.:
73082.52
Organism:
Homo sapiens (Human)
Description:
P04049
Residue:
648
Sequence:
MEHIQGAWKTISNGFGFKDAVFDGSSCISPTIVQQFGYQRRASDDGKLTDPSKTSNTIRVFLPNKQRTVVNVRNGMSLHDCLMKALKVRGLQPECCAVFRLLHEHKGKKARLDWNTDAASLIGEELQVDFLDHVPLTTHNFARKTFLKLAFCDICQKFLLNGFRCQTCGYKFHEHCSTKVPTMCVDWSNIRQLLLFPNSTIGDSGVPALPSLTMRRMRESVSRMPVSSQHRYSTPHAFTFNTSSPSSEGSLSQRQRSTSTPNVHMVSTTLPVDSRMIEDAIRSHSESASPSALSSSPNNLSPTGWSQPKTPVPAQRERAPVSGTQEKNKIRPRGQRDSSYYWEIEASEVMLSTRIGSGSFGTVYKGKWHGDVAVKILKVVDPTPEQFQAFRNEVAVLRKTRHVNILLFMGYMTKDNLAIVTQWCEGSSLYKHLHVQETKFQMFQLIDIARQTAQGMDYLHAKNIIHRDMKSNNIFLHEGLTVKIGDFGLATVKSRWSGSQQVEQPTGSVLWMAPEVIRMQDNNPFSFQSDVYSYGIVLYELMTGELPYSHINNRDQIIFMVGRGYASPDLSKLYKNCPKAMKRLVADCVKKVKEERPLFPQILSSIELLQHSLPKINRSASEPSLHRAAHTEDINACTLTTSPRLPVF
  
Inhibitor
Name:
BDBM50237711
Synonyms:
4-(4-(2-chlorophenyl)-2-phenyl-1H-imidazol-5-yl)pyridine | 4-[5-(2-Chloro-phenyl)-2-phenyl-3H-imidazol-4-yl]-pyridine | CHEMBL404842
Type:
Small organic molecule
Emp. Form.:
C20H14ClN3
Mol. Mass.:
331.798
SMILES:
Clc1ccccc1-c1[nH]c(nc1-c1ccncc1)-c1ccccc1
Structure:
Search PDB for entries with ligand similarity: